{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:06:18Z","timestamp":1790049978798,"version":"4.0.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:p>The Vitiligo Noticeability Scale (VNS) is a patient-reported outcome that assesses treatment success. It was originally validated by measuring the cosmetic acceptability of a single target patch before and after treatment. We further investigated the psychometric properties of the VNS and determined if it could be used as a global measure of vitiligo noticeability by using in-trial data from a phase II randomized trial (NCT04927975) assessing upadacitinib, an oral selective Janus kinase inhibitor, in patients with nonsegmental vitiligo. We found the VNS to be a valid and reliable global measure that can differentiate between clinically distinct groups and is sensitive to change.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf391","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:17:47Z","timestamp":1760012267000},"page":"170-172","source":"Crossref","is-referenced-by-count":1,"title":["Psychometric properties of the Vitiligo Noticeability Scale using data from a phase II randomized study of upadacitinib in adults with nonsegmental vitiligo"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"Khaled","family":"Ezzedine","sequence":"first","affiliation":[{"name":"Department of Dermatology, H\u00f4pital Henri Mondor, APHP , Cr\u00e9teil ,","place":["France"]},{"name":"EA 7379 EpidermE, Universit\u00e9 Paris-Est Cr\u00e9teil (UPEC) , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8632-1396","authenticated-orcid":false,"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1755-6210","authenticated-orcid":false,"given":"Mary\u00a0Kate","family":"Ladd","sequence":"additional","affiliation":[{"name":"Evidera , Wilmington, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1781-8197","authenticated-orcid":false,"given":"Robin","family":"Pokrzywinski","sequence":"additional","affiliation":[{"name":"Evidera , Wilmington, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5773-131X","authenticated-orcid":false,"given":"Karin S","family":"Coyne","sequence":"additional","affiliation":[{"name":"Evidera , Wilmington, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Sen","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4785-0670","authenticated-orcid":false,"given":"Bethanee J","family":"Schlosser","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5975-8519","authenticated-orcid":false,"given":"Jung Min","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Vincent\u2019s Hospital, College of Medicine, The Catholic University of Korea , Suwon ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2632-015X","authenticated-orcid":false,"given":"Heidi S","family":"Camp","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3137-5601","authenticated-orcid":false,"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[{"name":"Photomedicine and Photobiology Research Unit, Department of Dermatology, Henry Ford Health , Detroit, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026010607271042900_ljaf391-B1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-5945-14-10","article-title":"Survey and online discussion groups to develop a patient-rated outcome measure on acceptability of treatment response in vitiligo","volume":"14","author":"Tour","year":"2014","journal-title":"BMC Dermatol"},{"key":"2026010607271042900_ljaf391-B2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.14208","article-title":"Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success","volume":"174","author":"Batchelor","year":"2016","journal-title":"Br J Dermatol"},{"key":"2026010607271042900_ljaf391-B3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjd.21671","article-title":"Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability","volume":"187","author":"Batchelor","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026010607271042900_ljaf391-B4","doi-asserted-by":"crossref","first-page":"S499","DOI":"10.1016\/j.jval.2023.09.2693","article-title":"PCR256 Correlation of patient-reported vitiligo noticeability scale with physician-assessed facial vitiligo area scoring index responses: post hoc analyses from the TRuE-V trials of ruxolitinib cream in vitiligo","volume":"26","author":"Wolkerstorfer","journal-title":"Value Health"},{"key":"2026010607271042900_ljaf391-B5","doi-asserted-by":"crossref","first-page":"102655","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo\u00ad-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf391\/64602735\/ljaf391.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/170\/64602735\/ljaf391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/1\/170\/64602735\/ljaf391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:27:22Z","timestamp":1767702442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/1\/170\/8280186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf391","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,29]]}}}